Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
161.46
-2.62 (-1.60%)
Mar 5, 2026, 4:00 PM EST - Market closed
Axsome Therapeutics Stock Forecast
Stock Price Forecast
The 17 analysts with 12-month price forecasts for Axsome Therapeutics stock have an average target of 209.18, with a low estimate of 162 and a high estimate of 260. The average target predicts an increase of 29.56% from the current stock price of 161.46.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Axsome Therapeutics stock from 17 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 8 | 9 | 9 | 9 | 7 |
| Buy | 11 | 11 | 11 | 11 | 11 | 9 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 18 | 19 | 20 | 20 | 21 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Buy Maintains $248 → $251 | Strong Buy | Maintains | $248 → $251 | +55.46% | Feb 24, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $205 → $220 | Strong Buy | Maintains | $205 → $220 | +36.26% | Feb 24, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $219 → $222 | Buy | Maintains | $219 → $222 | +37.50% | Feb 24, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $193 → $202 | Buy | Maintains | $193 → $202 | +25.11% | Feb 24, 2026 |
| Wolfe Research | Wolfe Research | Buy Initiates $230 | Buy | Initiates | $230 | +42.45% | Feb 24, 2026 |
Financial Forecast
Revenue This Year
1.03B
from 638.50M
Increased by 61.00%
Revenue Next Year
1.59B
from 1.03B
Increased by 54.38%
EPS This Year
0.82
from -3.68
EPS Next Year
9.16
from 0.82
Increased by 1,018.12%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 1.3B | 2.0B | |||
| Avg | 1.0B | 1.6B | |||
| Low | 819.9M | 1.1B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 108.5% | 94.9% | |||
| Avg | 61.0% | 54.4% | |||
| Low | 28.4% | 11.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 5.24 | 15.76 | |||
| Avg | 0.82 | 9.16 | |||
| Low | -1.88 | 2.74 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 1,824.5% | |||
| Avg | - | 1,018.1% | |||
| Low | - | 235.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.